BNR

Burning Rock Biotech

15.75 USD
-1.30
7.62%
At close Updated Dec 12, 4:00 PM EST
Pre-market
After hours
15.71
-0.04
0.25%
1 day
-7.62%
5 days
-17.11%
1 month
28.99%
3 months
89.76%
6 months
290.82%
Year to date
113.13%
1 year
126.95%
5 years
-93.61%
10 years
-93.61%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 674

0
Funds holding %
of 7,507 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™